Medpace (NASDAQ:MEDP) & Seer (NASDAQ:SEER) Head to Head Survey

Seer (NASDAQ:SEER) and Medpace (NASDAQ:MEDP) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, risk and institutional ownership.

Earnings & Valuation

This table compares Seer and Medpace”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seer	$16.58 million	6.35	-$73.60 million	($1.22)	-1.56
Medpace	$2.53 billion	6.84	$451.12 million	$17.06	36.37

Medpace has higher revenue and earnings than Seer. Seer is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

75.2% of Seer shares are owned by institutional investors. Comparatively, 78.0% of Medpace shares are owned by institutional investors. 11.3% of Seer shares are owned by insiders. Comparatively, 20.5% of Medpace shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Seer and Medpace’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Seer	-478.05%	-27.23%	-23.99%
Medpace	17.67%	110.15%	24.84%

Analyst Ratings

This is a summary of recent recommendations for Seer and Medpace, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seer	1	0	0	2	3.00
Medpace	0	9	3	0	2.25

Seer presently has a consensus target price of $4.00, suggesting a potential upside of 110.53%. Medpace has a consensus target price of $595.20, suggesting a potential downside of 4.07%. Given Seer’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Seer is more favorable than Medpace.

Risk and Volatility

Seer has a beta of 1.5, indicating that its share price is 50% more volatile than the S&P 500. Comparatively, Medpace has a beta of 1.15, indicating that its share price is 15% more volatile than the S&P 500.

Summary

Medpace beats Seer on 11 of the 15 factors compared between the two stocks.

About Seer

Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. The company intends to sell its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It operates in China, Australia, Eastern Europe, Israel, and Japan. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.

About Medpace

Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH.